tirzepatide heart failure trial 📌 Most viewed this week from JAMA: In patients with cardiometabolic #HFpEF, #semaglutide and #tirzepatide reduced the risk of hospitalization for or all-cause mortality vs sitagliptin, but offered no New in the January 30,

We prioritize your safety by ensuring that any treatment planwhether it involves a single medication or a combinationis appropriate for your specific needs

It is not recommended in severe gastrointestinal disease

HENDERSON, NV, March 12, 2025 (GLOBE NEWSWIRE) -- PatchMD, a leading innovator in transdermal nutrient delivery, is excited to announce the launch of its new GLP-1 Support Patch Collectiona targeted solution designed to complement individuals using GLP-1 receptor agonist medications such as Ozempic, Wegovy, and Mounjaro for weight management

Reduced Inflammation & Joint Discomfort: Weight loss combined with improved metabolic function may reduce systemic inflammation

Without that context, its easy to over or underestimate risk